141 related articles for article (PubMed ID: 27609023)
1. A 19-Gene expression signature as a predictor of survival in colorectal cancer.
Abdul Aziz NA; Mokhtar NM; Harun R; Mollah MM; Mohamed Rose I; Sagap I; Mohd Tamil A; Wan Ngah WZ; Jamal R
BMC Med Genomics; 2016 Sep; 9(1):58. PubMed ID: 27609023
[TBL] [Abstract][Full Text] [Related]
2. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
Arango D; Laiho P; Kokko A; Alhopuro P; Sammalkorpi H; Salovaara R; Nicorici D; Hautaniemi S; Alazzouzi H; Mecklin JP; Järvinen H; Hemminki A; Astola J; Schwartz S; Aaltonen LA
Gastroenterology; 2005 Sep; 129(3):874-84. PubMed ID: 16143127
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients.
Horiuchi A; Iinuma H; Akahane T; Shimada R; Watanabe T
Oncol Rep; 2012 May; 27(5):1384-92. PubMed ID: 22267128
[TBL] [Abstract][Full Text] [Related]
6. Molecular staging for survival prediction of colorectal cancer patients.
Eschrich S; Yang I; Bloom G; Kwong KY; Boulware D; Cantor A; Coppola D; Kruhøffer M; Aaltonen L; Orntoft TF; Quackenbush J; Yeatman TJ
J Clin Oncol; 2005 May; 23(15):3526-35. PubMed ID: 15908663
[TBL] [Abstract][Full Text] [Related]
7. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients.
Sveen A; Ågesen TH; Nesbakken A; Meling GI; Rognum TO; Liestøl K; Skotheim RI; Lothe RA
Clin Cancer Res; 2012 Nov; 18(21):6001-10. PubMed ID: 22991413
[TBL] [Abstract][Full Text] [Related]
8. DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.
Bigagli E; De Filippo C; Castagnini C; Toti S; Acquadro F; Giudici F; Fazi M; Dolara P; Messerini L; Tonelli F; Luceri C
Cell Oncol (Dordr); 2016 Dec; 39(6):545-558. PubMed ID: 27709558
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
10. A plasma microRNA panel for early detection of colorectal cancer.
Wang S; Xiang J; Li Z; Lu S; Hu J; Gao X; Yu L; Wang L; Wang J; Wu Y; Chen Z; Zhu H
Int J Cancer; 2015 Jan; 136(1):152-61. PubMed ID: 23456911
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.
Fukushima Y; Iinuma H; Tsukamoto M; Matsuda K; Hashiguchi Y
Oncol Rep; 2015 Feb; 33(2):573-82. PubMed ID: 25421755
[TBL] [Abstract][Full Text] [Related]
12. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
13. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a blood-based 18-gene expression signature in colorectal cancer.
Xu Y; Xu Q; Yang L; Ye X; Liu F; Wu F; Ni S; Tan C; Cai G; Meng X; Cai S; Du X
Clin Cancer Res; 2013 Jun; 19(11):3039-49. PubMed ID: 23536436
[TBL] [Abstract][Full Text] [Related]
15. Detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CK20 mRNAS.
Oberg AN; Lindmark GE; Israelsson AC; Hammarström SG; Hammarström ML
Int J Cancer; 2004 Aug; 111(1):101-10. PubMed ID: 15185350
[TBL] [Abstract][Full Text] [Related]
16. CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpression correlates with radiation response in colorectal cancer.
Huang MY; Wang JY; Chang HJ; Kuo CW; Tok TS; Lin SR
Oncol Rep; 2011 May; 25(5):1297-306. PubMed ID: 21344162
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
18. A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients.
Shi M; Beauchamp RD; Zhang B
PLoS One; 2012; 7(7):e41292. PubMed ID: 22844451
[TBL] [Abstract][Full Text] [Related]
19. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
Schell MJ; Yang M; Missiaglia E; Delorenzi M; Soneson C; Yue B; Nebozhyn MV; Loboda A; Bloom G; Yeatman TJ
Clin Cancer Res; 2016 Feb; 22(3):734-45. PubMed ID: 26446941
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Chang W; Gao X; Han Y; Du Y; Liu Q; Wang L; Tan X; Zhang Q; Liu Y; Zhu Y; Yu Y; Fan X; Zhang H; Zhou W; Wang J; Fu C; Cao G
Gut; 2014 Sep; 63(9):1457-67. PubMed ID: 24173294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
